The prognostic marker NRlP1 is associated with tumor progression and immune infiltration in acute myeloid leukemiaOA

Acute myeloid leukemia(AML)is a clinically aggressive hematologic malignancy characterized by high relapse rates and treatment resistance,highlighting the need for novel biomarkers to improve clinical outcomes.In this study,we explore the roles of nuclear receptor-interacting protein 1(NRiP1)in AML,focusing on its associations with tumor progression and immune infiltration.Analysis of public AML gene expression datasets reveals that NRIP1 expression is significantly increased in AML patients.Those with high NRIP1 expression have markedly shorter overall survival than those with low expression.Furthermore,NRiP1 expression is significantly associated with the infiltration of diverse immune cells,including B cells,dendritic cells,T cells,mast cells,eosinophils,and T helper cells,suggesting that NRiP1 may be a regulator of immune cell infiltration.Functional enrichment analysis indicates that NRiP1 and its interacting partners are involved in tumorigenesis,immune microenvironment remodeling,and metabolic reprogramming.Survival analysis confirms the prognostic value of NRiP1.Importantly,functional validation in AML cell lines confirms that NRiP1 knockdown suppresses proliferation and induces apoptosis.Our study identifies NRIP1 as a multifaceted regulator that promotes AML by driving tumor progression,regulating immune cell infiltration,and modulating ferroptosis,highlighting its role as a novel prognostic biomarker.